$VEEV

Michael Burry Remains Bullish on Veeva but Trimmed His Position. What This Means for VEEV Stock.

Veeva Systems reported a 37% increase in net income to $273.4M and raised fiscal 2027 revenue guidance to $3.682B-$3.687B. Michael Burry trimmed his position but remains bullish, citing the company's intrinsic value and growth potential. Analysts expect Q3 EPS of $1.68 and have raised price targets, with a consensus 'Moderate Buy' rating and $292.52 average target.

Original reporting
Published Sep 9, 2026, 5:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 5:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Michael Burry Remains Bullish on Veeva but Trimmed His Position. What This Means for VEEV Stock. — source image
Decision brief

The 30-second read

$VEEVBullishHigh
01

Why it matters

The earnings beat and raised guidance reinforce Veeva's growth narrative, likely supporting further price appreciation.

02

Market read

Strong earnings and guidance lift Veeva's outlook, with potential spillover to the broader health‑tech sector.

03

What to watch

Potential headwinds from slower pharma spending or competitive pressure from emerging SaaS rivals.

Relevance 8/10Novelty 8/10Timing: before Veeva's next earnings on Nov 19, 2026

Background

Veeva Systems is a leading provider of cloud‑based software for the life‑sciences industry, known for its Vault platform.

Company-level read

Ticker impact

$VEEVBullishHigh confidence
Context

Veeva Systems reported Q3 earnings with 37% net income growth and raised FY2027 guidance, while Michael Burry trimmed his stake but remained bullish.

Expected impact

Potential upside of 5‑10% as investors digest the beat and guidance.

Evidence & confidence

Revenue and earnings beat, higher guidance, and continued analyst upgrades indicate momentum.

Market effects

Life‑sciences SaaS sector may see broader optimism from Veeva's results.

U.S. tech and healthcare indices could receive a modest lift.

Limited to investors focused on cloud‑based life‑sciences software.

Counterpoint

Burry's trim signals valuation concerns; some investors may view the stock as overbought.

Key entities

  • Michael Burry

    Renowned value investor who trimmed his Veeva position but remains bullish.

  • Needham

    Raised target price to $310 on strong CRM wins.

Related articles

$VEEVMed

CFRA upgrades Veeva Systems (VEEV) to a Buy

CFRA upgraded Veeva Systems (VEEV) to Buy with a new price target. The consensus rating is Moderate Buy with an average target of $293.57. Veeva reported Q2 revenue of $927.96M and net profit of $273.43M, up from $789.08M and $200.31M last year. Insider sentiment is negative, with 63 insiders selling shares.

$VEEVMedAI 8/10

Veeva Rises on Sales and Margin Gains, Guidance Raise

Veeva Systems (VEEV) reported Q2 fiscal 2027 revenue of $928M, up 18% YoY, with non-GAAP operating income of $415.9M. The company raised guidance to $3.687B in revenue and $9.21 in non-GAAP EPS. VEEV shares have risen 25% YTD, supported by strong institutional demand and robust fundamentals, including 3-year sales and EPS growth rates of 14.1% and 21.6%, respectively.

$VEEVHighAI 8/10

Watch Veeva, CrowdStrike, and More

Veeva Systems (VEEV) reported Q2 non-GAAP EPS of $2.35, revenue growth of 17.6% Y/Y to $928M, and raised its Q3 revenue forecast. CrowdStrike (CRWD) posted 25.6% Y/Y revenue growth to $1.47B. Dycom Industries (DY) fell 11.6% despite 45.6% Y/Y revenue growth to $2.01B due to segment pressures and higher costs.

$VEEVHighAI 8/10

Veeva (VEEV) Q2 2027 Earnings Call Transcript

Veeva Systems (VEEV) reported Q2 2027 revenues of $928.0 million, up 18% YoY, driven by growth in commercial and R&D segments. Subscription revenues rose 16% to $766.8 million. Non-GAAP operating income was $415.9 million, with a 44.8% margin. The company raised FY 2027 revenue guidance to $3.682B-$3.687B and EPS guidance to $9.21. Management highlighted strong adoption of Vault CRM and Data Cloud solutions, with 12 top 20 biopharmas committed to Vault CRM. Risks include the launch of the new Fa

$VEEVHighAI 9/10

VEEV Looks 5.0% Undervalued on GF Value™

Veeva Systems (VEEV) shares rose 9% after-hours on August 30, 2026, following stronger-than-expected Q2 results and raised full-year guidance. GF Value™ estimates VEEV as 5.0% undervalued at $276.69, with a GF Score™ of 95. Subscription revenues grew 16% to $766.8M. Insiders sold $18.1M in shares, while 8 gurus hold the stock, with 7 adding positions.